On July 11, 2023, the Audit Committee of the Board of Directors (the “Audit Committee”) of Elite Pharmaceuticals, Inc. (the “Company”) approved the appointment, effective July 11, 2023, of Mazers USA LLP (“Mazers”) as the Company’s new independent registered public accounting firm to audit the Company’s consolidated financial statements for the year ending March 31, 2024. The Audit Committee also dismissed Buchbinder Tunick & Company LLP (“Buchbinder”) as the Company’s independent registered public accounting firm, effective as of July 12, 2023.